Prostamax
Also known as: Prostate bioregulator, Lys-Glu-Asp-Pro
Prostamax (also called Prostate bioregulator or Lys-Glu-Asp-Pro) is a khavinson prostate bioregulator. Prostamax is a peptide preparation derived from prostate tissue and marketed in the Khavinson tradition. It is a complex of low-molecular-weight peptides rather than a single characterised compound, so no receptor, sequence or signalling mechanism can be specified for it.
For research use only.
Key Facts
- CAS
- 473578-47-1
- Molecular Weight (MW)
- 487.5 g/mol
- Half-life
- —
- FDA status
- Not Approved
- Administration Route
- Subcutaneous
- Frequency
- —
- Last updated
- Aug 30, 2026
- Reviewed
- Aug 30, 2026
- Targets
- Prostate epithelium (proposed)
Vendor price snapshot
Price per mg is list price divided by vial size in milligrams when both are known from public vendor listings. Peptide Library does not sell peptides. Confirm live prices on the vendor site.
- Vendors listing this peptide
- 2
- Listed offers
- 2
- Price per mg range
- $2.75–$4.00/mg
Research summary
Peptide preparation derived from prostate tissue and sold as a prostate bioregulator in the Khavinson tradition. It is a mixture of low-molecular-weight peptides rather than a single characterised compound, so no specific mechanism can be attributed to it. It is not a treatment for benign prostatic hyperplasia or any other prostate condition, has no controlled trial evidence, and is not FDA-approved.
Peptide Library's Prostamax profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Protocol
- Dosage Range
- Vendor research protocols only
- Frequency
- —
- Cycle
- —
- Administration Route
- Subcutaneous
- Reconstitution Guide
- —
- Injection Sites
- AbdomenThigh
- Timing Notes
- Educational catalog only — not medical advice
Sequence & molecular data
| Molecular formula | C20H33N5O9 |
|---|---|
| Molecular weight | 487.5 g/mol |
| CAS number | 473578-47-1 |
| Appearance | White lyophilized powder |
| Formulation | Lyophilized Powder |
| PubChem CID | 9848296 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Prostamax is a peptide preparation derived from prostate tissue and marketed in the Khavinson tradition. It is a complex of low-molecular-weight peptides rather than a single characterised compound, so no receptor, sequence or signalling mechanism can be specified for it. The proposed mechanism follows the series hypothesis that peptides extracted from a tissue act preferentially on that tissue by modulating gene expression, with claimed effects on prostate epithelial function. The supporting literature is regional and largely uncontrolled, and no randomised trial has evaluated prostate outcomes.
Origin
Synthetic short peptide.
Targets
Studies
- [Deheterochromatinization of the chromatin in old age induced by oligopeptide bioregulator (Lys-Glu-Asp-Pro)]
- Microcalorimetric study of human blood lymphocytes culture at presence of copper, cadmium and prostamax
- [The influence of the peptide bioregulator prostamax on heterochromatin of human lymphocytes in situ]
- [The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats]
- Effects of short peptides on lymphocyte chromatin in senile subjects
Regulatory & research status
Prostamax is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Research-Only |
Benefits
Potential Side Effects
Side Effects
- Not characterized
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Prostamax: frequently asked questions
What is Prostamax?
Peptide preparation derived from prostate tissue and sold as a prostate bioregulator in the Khavinson tradition. It is a mixture of low-molecular-weight peptides rather than a single characterised compound, so no specific mechanism can be attributed to it. It is not a treatment for benign prostatic hyperplasia or any other prostate condition, has no controlled trial evidence, and is not FDA-approved.
How does Prostamax work?
Prostamax is a peptide preparation derived from prostate tissue and marketed in the Khavinson tradition. It is a complex of low-molecular-weight peptides rather than a single characterised compound, so no receptor, sequence or signalling mechanism can be specified for it.
Is Prostamax FDA approved?
No. Prostamax is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What peptides are similar to Prostamax?
Compounds most often compared with Prostamax include Bonomarlot, Bronchogen, Cardiogen and Cartalax. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- [Deheterochromatinization of the chromatin in old age induced by oligopeptide bioregulator (Lys-Glu-Asp-Pro)] — Georgian Med News, 2012External reference
- Microcalorimetric study of human blood lymphocytes culture at presence of copper, cadmium and prostamax — Georgian Med News, 2009External reference
- [The influence of the peptide bioregulator prostamax on heterochromatin of human lymphocytes in situ] — Biofizika, 2004External reference
- [The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats] — Adv Gerontol, 2006External reference
- Effects of short peptides on lymphocyte chromatin in senile subjects — Bull Exp Biol Med, 2004External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Aug 30, 2026 · Version 1
This Prostamax profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Prostamax research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →